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Fixed-dose drug combination decreases the risk of patient non-compliance and
should be considered in patients with chronic conditions like hypertension (1). Clini-
cally, combination therapy in hypertension treatment involving two or more drugs from
different classes can result in better drug efficacy and is recommended for the initial sta-
ge of hypertension treatment (2). The combination of atenolol and amlodipine signifi-
cantly decreases blood pressure and systolic blood pressure variability. In spontaneously
hypertensive rats, the synergistic effect between atenolol and amlodipine results in low-
ering and stabilizing of blood pressure (3). Both beta blockers and dihydropyridine cal-
cium antagonist are widely used in the treatment of hypertension. Their combination is
a logical choice and can also neutralize the side effects of each drug. Combination the-
rapy is likely to be the optimal way to control blood pressure and reduce blood pressure
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Multi-drug tablets of amlodipine besylate and atenolol
were prepared as either mono-layer (mixed matrix) or bi-
-layer tablets containing each drug in a separate layer by
using similar excipients and processing. Each tablet batch
was packed in strip and blister packs and kept under ac-
celerated temperature and humidity conditions. The sta-
bility of two tablet and packaging types was compared
by HPLC analysis after 0, 1, 3 and 4.5 months and expre-
ssed as the content of intact amlodipine and atenolol. The
content of atenolol did not decline regardless of tablet
and packaging type. Amlodipine content in bi-layer tab-
lets decreased to about 95 and 88% when packed in strips
and blisters, respectively. When prepared as mono-layer
tablets, the content decreased to 72 and 32%, respectively.
The study revealed that the bi-layer tablet formulation
was more stable than the mono-layer type. Further, the
stability was increased when the tablets were packed in
aluminium strips as compared to PVC blisters.
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variability in the treatment of hypertension as well as in prevention of stroke in hyper-
tension (4). The stability of the product, on the other hand, remains a pharmaceutical
challenge in multi-drug formulations.
Amlodipine besylate, like all members of 1,4-dihydropyridine calcium channel blo-
ckers, is photosensitive and liable to degradation both in solution and in solid state. Light
catalyses its oxidation to pyridine derivatives, such as amlox (2-(2-aminoethoxy)met -
hyl-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl pyridine), which
lack therapeutic effects (5). Forced degradation studies show amlodipine to be degrad-
ing slowly under thermal stress (more in solution than in solid state), degrading faster
under photo-stress (more rapidly under UV 366 nm than under 254 nm and less in natu-
ral light) and even more under acidic, alkaline and oxidative stress – the highest being in
alkaline conditions (6, 7). Another pharmaceutical problem is the reported incompatibi-
lity in the solid formulation between amlodipine besylate and lactose in the presence of
basic excipients (magnesium stearate) and water (8). Atenolol is reported to be photo-
reactive when exposed to UVA–UVB radiation with photodegradation increasing with a
decrease in the pH value. The main photodegradation product at pH 7.4 was identified
as 2-(4-hydroxyphenyl) acetamide (9).
This research work was designed to compare the stability of two types of tablets – a
mono-layer tablet containing amlodipine besylate and atenolol in the same matrix and a
bi-layer tablet containing amlodipine besylate and atenolol in separate layers. Similar
excipients, processing and storage conditions were applied for both tablet types and two
different packaging materials (aluminium and PVC) were used to study the influence of
packaging material. The results were obtained from HPLC analyses of drug content in
the tablets stored under accelerated temperature and humidity conditions.
EXPERIMENTAL
Materials
All the materials were generously provided by Quest Pharmaceuticals (P) Ltd, Ne-
pal. All raw materials used to manufacture the tablets were of pharmaceutical grade and
included amlodipine besylate BP (Cadila Pharma, India), atenolol IP (IPCA Laboratories,
India), maize starch IP (Universal Starch, India), microcrystalline cellulose (powder) IP
(Chemsfield, India), calcium hydrogen phosphate dihydrate IP (Enar Chemie, India), so-
dium starch glycolate IP (Universal Starch, India), magnesium stearate IP (Paras Fine
Organics, India), colloidal silicon dioxide IP (Degussa, Belgium) and erythrosine lake
colour ISI (Roha Dye Chem, India).
Chemicals and solvents for analysis: methanol, acetonitrile and water for HPLC (Li-
Chrosolv brand) were purchased from Merck Ltd, India. Triethylamine was a product of
Qualigens Fine Chemicals, India. Sodium octane sulphonate (1-octane sulphonic acid
sodium salt) for chromatography was purchased from Spectrochem, India, and o-phos-
phoric acid, from Central Drug House, India. All the chemicals used were of analytical
grade.
Working standards of amlodipine besylate and atenolol were also kind gifts from
Quest Pharmaceuticals (P).
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Manufacturing and packaging of tablets
Both types of tablets were manufactured in batches of ten thousand tablets each as
per formulae given in Table I. Three granulations were prepared separately – two single
ingredient granules of amlodipine and atenolol and one of mixed granules containing
both. All the granules were prepared by the wet granulation method using starch paste
as a binder. The active ingredients and colour (in amlodipine granules) were mixed with
the diluents using the geometrical dilution method manually and granulated by mixing
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Table I. Mono-layer (A) and bi-layer tablet formulations (B)




Microcrystalline cellulose (powder) 95.00
Calcium hydrogen phosphate dihydrate 90.00
Sodium starch glycolate 15.00
Magnesium stearate 1.00
Colloidal silicon dioxide 2.00




Microcrystalline cellulose (powder) 50.00
Calcium hydrogen phosphate dihydrate 40.00
Sodium starch glycolate 15.00
Magnesium stearate 1.00
Colloidal silicon dioxide 2.00





Microcrystalline cellulose (powder) 40.00
Calcium hydrogen phosphate dihydrate 32.00
Sodium starch glycolate 10.00
Magnesium stearate 1.00
Colloidal silicon dioxide 2.00
Total mass 185.00
Total mass of bi-layered tablet 350.00
with starch paste in a paddle type Mass Mixer (10 liter capacity, Grovers Equipments,
India). The wet mass were shredded from a 16 mesh sieve and dried in a fluidized bed
dryer (30 kg capacity, Kothari Pharma, India) at 50 °C until the moisture content (deter-
mined by a moisture balance, IR-30 Denver Instruments, USA) came to about 4.5%. Fi-
nally, the granules were sieved again from a 16 mesh sieve (1.19 mm), mixed with so-
dium starch glycolate and lubricated with magnesium stearate and colloidal silicon
dioxide as per their respective formulae.
The lubricated granules were compressed into mono-layer and bi-layer tablets us-
ing a 27-station double-sided Rotary Tablet Press (Cadmach, India). A set of round bi-
convex 10-mm diameter punches was used for both tablet types. Mono-layer tablets were
compressed at a theoretical average mass of 350 mg. Bi-layer parts were used to com-
press amlodipine (pink) and atenolol (white) as separate layers in the bi-layer tablet. The
mass of amlodipine layer was adjusted to 165 mg and atenolol layer to 185 mg, making
the final tablet mass 350 mg. Vacuum was employed in the suction port of the machine
to avoid mixing of the two granules.
Both types of tablets were then packed in strips and blisters of 10 tablets each. Strips
were prepared from 0.03 mm polylaminated aluminium foils (Hindalco, India) using a
strip packing machine (Kulbindra Engineering, India). Blisters were packed in 0.025 mm
heat sealing laquer (HSL)-coated aluminium foil (Hindalco, India) and 0.25 mm clear
transparent PVC (Fenoplast India) using a blister machine (Elmach Packaging, India).
Assay of amlodipine and atenolol
Instrumentation. – Isocratic HPLC System (Knauer, Germany) was used for the ana-
lysis. The solvent delivery system consisted of a Smartline HPLC pump model 1000 with
a 10-mL pump head. The detector was a spectrophotometer type Smartline UV 2500.
PC-based software Eurochrom 2000 for Windows, V.3.05, was employed for data acqui-
sition, processing and instrument control. A 20-mL loop was used for sample injection.
Reversed phase octadecyl silane (ODS) C-18 column stainless steel, 250 mm x 4.6 mm in-
ternal diameter, with 10 mm particle size (Eurosper 100-10, Knaur) was used as the ana-
lytical column. The analysis was carried out at a 1.5 mL min–1 flow rate and detection at
238 nm. Analytical columns were used at ambient laboratory temperature that was kept
within 22–27 °C with a room air conditioner.
Mobile phase preparation. – Mobile phase consisted of HPLC grade water/methanol/
acetonitrile (34:33:33) containing triethylamine (0.034%) and sodium octane sulphonate
(0.1%). The pH of the solution was adjusted to 2.8 with 50% o-phosphoric acid. The solu-
tion was sonicated for 5 min with a laboratory sonicator (6 l model, Medica Instruments,
India) and filtered from Axiva brand disc filters (0.45 mm; Axiva Sichem (P) Ltd, India)
using a vacuum filtration kit.
Standard preparation. – Amlodipine besylate accurately weighed to 69.00 mg (equiva-
lent to 50.00 mg amlodipine) was transferred to a 50-mL volumetric flask and dissolved
in about 25 mL of mobile phase by manual shaking and the volume was adjusted with
the mobile phase. An liquot (5 mL) of the above solution was transferred to a 100-mL
volumetric flask. Atenolol (50.00 mg) was dissolved in about 50 mL of mobile phase by
manual shaking and the final volume (100.00 mL) was adjusted with the mobile phase.
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The solution was finally filtered using a syringe filtration kit from Ultipore (N66 brand
0.2 mm membrane filter, 13 mm diameter; PALL Life Sciences, India).
Sample preparation. – Sample tablets were removed from their strip/blister and the
average mass of 20 tablets was determined. The tablets were crushed using a mortar and
pestle to fine powder. A quantity of powder equivalent to the average mass of the tab-
lets was accurately weighed and transferred to a 100-mL volumetric flask. The flask was
half-filled with the mobile phase and shaken manually for 10 minutes. The volume was
made up to 100 mL with the mobile phase and kept in the sonicator for 10 minutes. An
aliquot of the solution was centrifuged for 5 min at 2500 rpm; about 2 mL of the solution
was then filtered through a 0.2 mm Ultipore N66 membrane filter and kept in the sample
vial with an air tight lid.
Stability study. – The samples were kept in the stability chamber (Thermaolab, India)
set at accelerated storage conditions (10) of 40  2 °C and 75  5% relative humidity.
Contents of both amlodipine and atenolol in the samples were periodically monitored
by the HPLC analysis. Analyses were carried out at time 0 and after storage of 1, 2, 3,
and 4.5 months in the stability chamber. The comparison was statistically evaluated by
Student's t test.
RESULTS AND DISCUSSION
Amlodipine and atenolol combined in the same drug dosage form are gaining po-
pularity among pharmaceutical manufacturers. However, data on the stability of such
products are not disclosed and remain mostly with the manufacturer. As the combina-
tion of amlodipine and atenolol is not official in the therapeutic Compendia, quantita-
tive analyses of amlodipine (6, 11, 12) and atenolol (13, 14) in pharmaceutical dosage
forms are generally described by UV spectrophotometric and high performance liquid
chromatographic techniques. Determination of both components in multi-drug tablets is
done by various methods such as UV spectrophotometry, HPLC, and HPTLC (15, 16).
Resolution of multicomponent preparations is often a complex analytical problem
since combined substances may have different chemical structures but similar proper-
ties, e.g., chromatographic behaviour (13). Therefore, the development and validation of
the modified analytical method for the concomitant assay of amlodipine and atenolol
consumed considerable time of the research. The methods described in the literature for
the determination of amlodipine and atenolol (11, 12, 15, 16) were, in our conditions,
found to be unsuitable regarding the resolution of components, large tailing factors and
inconsistency. We based our method on the conditions described by Klinkenberg et al.
(11) but we had to adjust the mobile phase composition. The analytical variables were
optimized to obtain the desired chromatographic characteristics, including resolution of
the components, peak symmetry (tailing factors at least less than 2) and theoretical plate
numbers over 1000 (10).
Validation of the HPLC method
As we adjusted the assay conditions, validation of the modified method was neces-
sary. The method was validated through injection repeatability, linearity tests, recovery
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test, LOD, LOQ, and accuracy (11). In the injection repeatability test, the relative stan-
dard deviations (RSD) of the peak area of six consecutive injections were found to be 0.8
and 0.7% for atenolol and amlodipine, respectively. Linearity test for the response was
conducted by using five standard solutions containing 40, 45, 50, 55, and 60 g mL–1 of
amlodipine base and 400, 450, 500, 550, and 600 g mL–1 of atenolol, respectively. Re-
gression analysis showed satisfactory results with the squared value of the Pearson pro-
duct moment correlation coefficient of 0.9966 for amlodipine and 0.9989 for atenolol.
The recovery test (in triplicate, the standard addition method) was carried out using
simulated tablet samples (samples of a known quantity of the drug along with placebo
mixtures of excipients in the same composition as in the actual mono-layer tablets) of 90,
100 and 110% strength. The test resulted in mean recovery of 99.8%  for amlodipine and
99.5%  for atenolol and showed acceptable accuracy. The mean recovery was in good
agreement with the published data for amlodipine (12) and atenolol (13, 14). Limit of de-
tection (LOD) was found to be 3.63 and 5.31 mg mL–1 for amlodipine and atenolol, re-
spectively. Limit of quantification (LOQ) was 11.01 and 16.09 mg mL–1 for amlodipine
and atenolol, respectively. The values for LOD and LOQ were rather high compared to
the values of Klinkenberg et al. (11), who were determining the residues of amlodipine
alone, whereas, we were dealing with a mixed drug system.
Specificity tests were carried out by comparing the chromatographic peaks of the
mobile phase only, excipients (placebo mixture) added to the mobile phase and treated
like the sample and the standard containing amlodipine and atenolol. Placebo mixture
was prepared by mixing the same excipients in the same composition as in the actual
mono-layer tablets. Placebo was added to standard solutions in the same proportion
that would be contained in the dilution of the actual formulation. The chromatogram
with only placebo showed no significant peaks in the positions where the principal peaks
would appear (Fig. 1). The chromatographic results of the standard with and without
addition of the excipients were compared and no changes were observed after addition
of excipients. It is known that atenolol can be determined in the presence of its major
degradation product (14) and therefore the measurements were focused on drugs con-
tent alone.
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Fig. 1. A representative chromatogram and the chromatographic parameters of a standard solution
containing amlodipine (tR = 4.95  0.11 min) and atenolol (tR = 1.85  0.01 min). HPLC conditions:
column: RP18 (ODS, 4.6 x 250 mm); eluent: water/methanol/acetonitrile (34:33:33) with triethylamine
(0.034%) and sodium octane sulphonate (0.1%), pH 2.8; flow rate: 1.5 mL min–1; detection: UV 238 nm.
305
S. Aryal and N. Škalko-Basnet: Stability of amlodipine besylate and atenolol in multi-component tablets of mono-layer and bi-layer

































































































































































































































































































































































































































































The stability test results in terms of the average content of amlodipine and atenolol
per tablet, in percentage with respect to the labeled amount, are presented in Table II.
The quantity of atenolol remained fairly constant in both strip and blister packing until
the end of the stability study period (4.5 months). No significant degradation was ob-
served in either the mono-layer or bi-layer tablets (Table II).
Amlodipine content in the strip packaging decreased, in the mono-layer tablets, to
72.2% (p < 0.005). When prepared as bi-layer tablets and packed in strips, a significant
decrease (p < 0.005) was observed only after 4.5 months of storage. To be sure that the
values were the result of degradation and not of variability in tablet mass, we deter-
mined the tablet mass variation for the mono-layer type (+2.2 and –1.7%) and the bi-layer
type (+2.3 and –3.1 %). Moreover, we also determined the individual mass variations in
separate layers and found them to be +4.3 and –3.7% for the atenolol layer and +3.8 and
–6.2% for the amlodipine layer. Taking into account individual mass variations, the de-
crease in the amlodipine content in bi-layer tablets packed in strips does not represent a
significant degradation. Amlodipine content sharply decreased in the blister packed tab-
lets – both in the mono-layer (p < 0.005) and bi-layer formulations. The decrease was
more dramatic in the mono-layer type dropping to about 32.3% within 4.5 months (Table
II). This significant decline in content (p < 0.005) is clearly the result of amlodipine deg-
radation since it is more than what could be contributed to mass variation.
The stability results suggest that atenolol was fairly stable in both formulations in
strip packing (Table II). The variations in atenolol content (from 97.1 to 102.0%) corre-
spond to the tablet mass variation +4.3 to –3.7%. The contribution from tablet mass vari-
ation can be expected to be a little higher in bi-layer tablets than in mono-layer tablets.
On the other hand, the content of amlodipine in mono-layer strips, mono-layer and bi-
-layer blisters was gradually decreasing with a significant change (more than 5%) as per
ICH (10). The results (Table II) indicate that, in regard to amlodipine content, strip pack-
aging is preferable to blister packaging (p < 0.005). Moreover, the bi-layer type is signifi-
cantly (p < 0.005) more suitable than the mono-layer type for all combined type formula-
tions. Although the manufacturing of bi-layer tablets requires more time, skill and finan-
cial resources, it appears to be a preferable choice for combined drugs formulations.
As no literature data are available on the stability of the combination dosage forms
of these two drugs, we expect that more research will be done into the stability problems
of such combined formulations.
CONCLUSIONS
Amlodipine degraded more rapidly than atenolol in both types of tablets and pack-
ing materials. The drugs in bi-layered tablets were found to be more stable than in mo-
no-layer tablets, and strip packaging was found to be superior to blister packaging con-
sidering the stability parameter. We recommend the bi-layered type tablets packed in
aluminium strips as a preferable choice for formulation of amlodipine and atenolol as
single dosage form tablets. It would be interesting to confirm the degradation products
of both drugs, and to quantify them.
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S A @ E T A K
Stabilnost amlodipin besilata i atenola u jednoslojnim i dvoslojnim tabletama
SAJJAN ARYAL i NATAŠA ŠKALKO-BASNET
Tablete s amlodipinom i atenololom pripremljene su ili u obliku jednoslojne tablete
(miješani matriks) ili kao dvoslojne tablete (lijekovi u zasebnim slojevima) koriste}i sli-
~ne pomo}ne tvari i uvjete tabletiranja. Tablete su pakirane u dvije vrste pakiranja, alu-
minijske folije (strip) ili PVC (blister) i ~uvane u uvjetima ubrzanog starenja. Stabilnost
je odre|ivana pomo}u HPLC metode nakon 0, 1, 2, 3 i 4,5 mjeseci i izraena kao sadraj
intaktnog lijeka.
Sadraj atenolola nije se zna~ajno promijenio bez obzira na tip tablete ili pakiranje.
Sadraj amlodipina u dvoslojnim tabletama smanjio se na 95% (tablete u strip pakiranju)
i 88% (tablete u blister pakiranju). Istodobno, u jednoslojnom tipu kombiniranih tableta
sadraj se smanjio na 72% (strip pakiranje) i 32% (blister pakiranje).
Rezultati pokazuju da su dvoslojne tablete s amlodipinom i atenololom stabilnije od
jednoslojnih. Štoviše, pakiranje tableta u aluminijsku foliju u obliku strip pakiranja po-
ve}ava njihovu stabilnost u usporedbi s PVC pakirnim materijalom (blister).
Klju~ne rije~i: amlodipin, atenolol, jednoslojna, dvoslojna tableta, stabilnost
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